Role of the angiopoietin/Tie system in pregnancy (Review)

Experimental and Therapeutic Medicine

Volumn 9, Issue 4, 2015, Pages 1091-1096

  Kappou, D ^a   Sifakis, Stavros ^b   Konstantinidou, A ^c   Papantoniou, N ^a   Spandidos, D A ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiopoietin 1; Angiopoietin 2; Angiopoietin Tie system; Intrauterine growth restriction; Placenta; Preeclampsia; Pregnancy; Vascular endothelium specific receptor tyrosine kinase tie 2

Indexed keywords

ANGIOPOIETIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TIE RECEPTOR; TRANSCRIPTION FACTOR FOXO; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL MATURATION; CELL SURVIVAL; HUMAN; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; PATHOGENESIS; PREECLAMPSIA; PREGNANCY COMPLICATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84922980432     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2280     Document Type: Article

References (65)

1. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
2. Maynard SE and Karumanchi SA: Angiogenic factors and preeclampsia. Semin Nephrol 31: 33-46, 2011.
3. Gourvas V, Dalpa E, Konstantinidou A, Vrachnis N, Spandidos DA and Sifakis S: Angiogenic factors in placentas from pregnancies complicated by fetal growth restriction (review). Mol Med Rep 6: 23-27, 2012.
4. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al: Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 208: 287. e1-287. e15, 2013.
5. Gómez Arriaga PI, Herraiz I, López Jiménez EA, Escribano D, Denk B and Galindo A: Uterine artery Doppler and sFlt 1/PlGF ratio: Prognostic value in early onset pre eclampsia. Ultrasound Obstet Gynecol 43: 525-532, 2014.
6. Andraweera PH, Dekker GA and Roberts CT: The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 18: 436-457, 2012.
7. Charnock Jones DS: Soluble flt 1 and the angiopoietins in the development and regulation of placental vasculature. J Anat 200: 607-615, 2002.
8. Park SW, Yun JH, Kim JH, Kim KW, Cho CH and Kim JH: Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes 63: 3057-3068, 2014.
9. Saharinen P, Eklund L, Pulkki K, Bono P and Alitalo K: VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17: 347-362, 2011.
10. Mussap M, Cibecchini F, Noto A and Fanos V: In search of biomarkers for diagnosing and managing neonatal sepsis: The role of angiopoietins. J Matern Fetal Neonatal Med 26 (Suppl 2): 24-26, 2013.
11. Thurston G: Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314: 61-68, 2003.
12. Thomas M and Augustin HG: The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12: 125-137, 2009.
13. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin 2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
14. Davis S, Aldrich TH, Jones PF, et al: Isolation of angiopoietin 1, a ligand for the TIE2 receptor, by secretion trap expression cloning. Cell 87: 1161-1169, 1996.
15. Khan AA, Sandhya VK, Singh P, et al: Signalling network map of endothelial TEK tyrosine kinase. J Signal Transduct 2014: 173026, 2014.
16. Daly C, Wong V, Burova E, et al: Angiopoietin 1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 18: 1060-1071, 2004.
17. Coffelt SB, Tal AO, Scholz A, et al: Angiopoietin 2 regulates gene expression in TIE2 expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 70: 5270-5280, 2010.
18. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T, Sukhatme VP, Woolf AS and Karumanchi SA: Activation of the orphan endothelial receptor Tie1 modifies Tie2 mediated intracellular signaling and cell survival. FASEB J 21: 3171-3183, 2007.
19. Augustin HG, Koh GY, Thurston G and Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin Tie system. Nat Rev Mol Cell Biol 10: 165-177, 2009.
20. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM and Yancopoulos GD: Angiopoietin 1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463, 2000.
21. Scharpfenecker M, Fiedler U, Reiss Y and Augustin HG: The Tie 2 ligand angiopoietin 2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 118: 771-780, 2005.
22. Daly C, Eichten A, Castanaro C, et al: Angiopoietin 2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73: 108-118, 2013.
23. Teichert Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD and Stewart DJ: Biological action of angiopoietin 2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49: 659-670, 2001.
24. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH and Jackson D: Angiopoietin 2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin 1. Dev Cell 3: 411-423, 2002.
25. Felcht M, Luck R, Schering A, et al: Angiopoietin 2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122: 1991-2005, 2012.
26. Fiedler U, Reiss Y, Scharpfenecker M, et al: Angiopoietin 2 sensitizes endothelial cells to TNF alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235-239, 2006.
27. Dunk C, Shams M, Nijjar S, Rhaman M, Qiu Y, Bussolati B and Ahmed A: Angiopoietin 1 and angiopoietin 2 activate trophoblast Tie 2 to promote growth and migration during placental development. Am J Pathol 156: 2185-2199, 2000.
28. Shim WS, Ho IA and Wong PE: Angiopoietin: A TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5: 655-665, 2007.
29. Brunckhorst MK, Xu Y, Lu R and Yu Q: Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol 184: 2285-2296, 2014.
30. Huang H, Bhat A, Woodnutt G and Lappe R: Targeting the ANGPT TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585, 2010.
31. Biel NM and Siemann DW: Targeting the Angiopoietin 2/Tie 2 axis in conjunction with VEGF signal interference. Cancer Lett: Oct 12, 2014 (Epub ahead of print).
32. Mazzieri R, Pucci F, Moi D, et al: Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512-526, 2011.
33. Goede V, Coutelle O, Neuneier J, et al: Identification of serum angiopoietin 2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab containing therapy. Br J Cancer 103: 1407-1414, 2010.
34. Helfrich I, Edler L, Sucker A, et al: Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15: 1384-1392, 2009.
35. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A and Jaffe RB: Human placental vascular development: Vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor A, angiopoietin 1, and angiopoietin 2. J Clin Endocrinol Metab 87: 4213-4224, 2002.
36. Zhang EG, Smith SK, Baker PN and Charnock Jones DS: The regulation and localization of angiopoietin 1, 2, and their receptor Tie2 in normal and pathologic human placentae. Mol Med 7: 624-635, 2001.
37. Leinonen E, Wathén KA, Alfthan H, Ylikorkala O, Andersson S, Stenman UH and Vuorela P: Maternal serum angiopoietin 1 and 2 and tie 2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 95: 126-133, 2010.
38. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, Masuyama H, Hiramatsu Y and Makino H: Elevated serum sFlt 1/Ang 2 ratio in women with preeclampsia. Nephron Clin Pract 106: c43 c50, 2007.
39. Seval Y, Sati L, Celik Ozenci C, Taskin O and Demir R: The distribution of angiopoietin 1, angiopoietin 2 and their receptors tie 1 and tie 2 in the very early human placenta. Placenta 29: 809-815, 2008.
40. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite role of angiopoietin 1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996.
41. Geva E, Ginzinger DG, Moore DH, Ursell PC and Jaffe RB: In utero angiopoietin 2 gene delivery remodels placental blood vessel phenotype: A murine model for studying placental angiogenesis. Mol Hum Reprod 11: 253-260, 2005.
42. Sato TN, Tozawa Y, Deutsch U, Wolburg Buchholz K, Fujiwara Y, Gendron Maguire M, Gridley T, Wolburg H, Risau W and Qin Y: Distinct roles of the receptor tyrosine kinases Tie 1 and Tie 2 in blood vessel formation. Nature 376: 70-74, 1995.
43. Wulff C, Wilson H, Dickson SE, Wiegand SJ and Fraser HM: Hemochorial placentation in the primate: Expression of vascular endothelial growth factor, angiopoietins, and their receptors throughout pregnancy. Biol Reprod 66: 802-812, 2002.
44. Steegers EA, von Dadelszen P, Duvekot JJ and Pijnenborg R: Pre eclampsia. Lancet 376: 631-644, 2010.
45. Kleinrouweler CE, Wiegerinck MM, Ris Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW and Pajkrt E; EBM CONNECT Collaboration: Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms like tyrosine kinase 1 and soluble endoglin in the prediction of pre eclampsia: A systematic review and meta analysis. BJOG 119: 778-787, 2012.
46. Sung JF, Fan X, Dhal S, Dwyer BK, Jafari A, El Sayed YY, Druzin ML and Nayak NR: Decreased circulating soluble Tie2 levels in preeclampsia may result from inhibition of vascular endothelial growth factor (VEGF) signaling. J Clin Endocrinol Metab 96: E1148-E1152, 2011.
47. Han SY, Jun JK, Lee CH, Park JS and Syn HC: Angiopoietin 2: A promising indicator for the occurrence of severe preeclampsia. Hypertens Pregnancy 31: 189-199, 2012.
48. Kappou D, Sifakis S, Androutsopoulos V, Konstantinidou A, Spandidos DA and Papantoniou N: Placental mRNA expression of angiopoietins (Ang) 1, Ang 2 and their receptor Tie 2 is altered in pregnancies complicated by preeclampsia. Placenta 35: 718-723, 2014.
49. Szpera-Gozdziewicz A and Breborowicz GH: Endothelial dysfunction in the pathogenesis of pre-eclampsia. Front Biosci (Landmark Ed) 19: 734-746, 2014.
50. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M and Honda Y: Hypoxia and vascular endothelial growth factor selectively up regulate angiopoietin 2 in bovine microvascular endothelial cells. J Biol Chem 274: 15732-15739, 1999.
51. Vuorela P, Matikainen MT, Kuusela P, Ylikorkala O, Alitalo K and Halmesmäki E: Endothelial tie receptor antigen in maternal and cord blood of healthy and preeclamptic subjects. Obstet Gynecol 92: 179-183, 1998.
52. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H, Yamasaki Y, Masuyama H, Hiramatsu Y and Makino H: Increase of serum angiopoietin 2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens 18: 1181-1188, 2005.
53. Gotsch F, Romero R, Kusanovic JP, et al: Preeclampsia and small for gestational age are associated with decreased concentrations of a factor involved in angiogenesis: Soluble Tie 2. J Matern Fetal Neonatal Med 21: 389-402, 2008.
54. Bolin M, Wiberg Itzel E, Wikström AK, Goop M, Larsson A, Olovsson M and Akerud H: Angiopoietin 1/angiopoietin 2 ratio for prediction of preeclampsia. Am J Hypertens 22: 891-895, 2009.
55. Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W and Verlohren S: The importance of repeated measurements of the sFlt 1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 42: 61-68, 2014.
56. Vrachnis N, Kalampokas E, Sifakis S, Vitoratos N, Kalampokas T, Botsis D and Iliodromiti Z: Placental growth factor (PlGF): A key to optimizing fetal growth. J Matern Fetal Neonatal Med 26: 995-1002, 2013.
57. Wang Y, Tasevski V, Wallace EM, Gallery ED and Morris JM: Reduced maternal serum concentrations of angiopoietin 2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. BJOG 114: 1427-1431, 2007.
58. Akolekar R, Casagrandi D, Skyfta E, Ahmed AA and Nicolaides KH: Maternal serum angiopoietin 2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 29: 847-851, 2009.
59. Schneuer FJ, Roberts CL, Ashton AW, Guilbert C, Tasevski V, Morris JM and Nassar N: Angiopoietin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes. Am J Obstet Gynecol 210: 345. e1 e9, 2014.
60. Findley CM, Cudmore MJ, Ahmed A and Kontos CD: VEGF induces Tie2 shedding via a phosphoinositide 3 kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 27: 2619-2626, 2007.
61. Regnault TR, Galan HL, Parker TA and Anthony RV: Placental development in normal and compromised pregnancies a review. Placenta 23 (Suppl A): S119-S129, 2002.
62. Tseng JJ, Hsu SL, Ho ES, Hsieh YT, Wen MC and Chou MM: Differential expression of angiopoietin 1, angiopoietin 2, and Tie receptors in placentas from pregnancies complicated by placenta accreta. Am J Obstet Gynecol 194: 564-571, 2006.
63. Vuorela P, Carpén O, Tulppala M and Halmesmäki E: VEGF, its receptors and the tie receptors in recurrent miscarriage. Mol Hum Reprod 6: 276-282, 2000.
64. Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G and Kaye S: Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 108: 250-258, 2013.
65. Gerald D, Chintharlapalli S, Augustin HG and Benjamin LE: Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 73: 1649-1657, 2013.